UPDATE: Jefferies Raises PT to $8.30 on Boston Scientific Corporation on Favorable 5-Year Outlook

Jefferies maintained Boston Scientific Corporation BSX with a Hold rating and raised the price target from $7.60 to $8.30. Jefferies noted, "Echoing a common refrain in medtech these days, the message from Boston's investor day was that stabilizing core markets and a concerted effort to diversify away from these markets (both products and geographies) will drive better growth. Margins will expand and BSX will slowly return to mid-single-digit sales growth and double-digit earnings. Despite the risks in the outlook it seems already priced into the stock so we stay at Hold." Boston Scientific Corporation closed at $7.59 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!